This review is a concise summary of the important pharmacological and clinical characteristics of vedolizumab (Entyvio®), which is available in Australia and reimbursed on the PBS for the treatment of adult patients with moderate-to-severe ulcerative
colitis (UC) or Crohn’s disease (CD) who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or tumour necrosis factor (TNF)-α antagonists.
Expert commentary on the use of vedolizumab from a clinical perspective is provided by Professor Rupert Leong, Senior Staff Specialist Gastroenterologist, Head of Concord Hospital Inflammatory Bowel Disease Service and foundation director of IBD Sydney Organisation.
Please login below to download this issue (PDF)